Calistoga Pharmaceuticals Announces Presentation on CAL-101 at American Society of Clinical Oncology Annual Meeting

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.